Traditional FDA approval is based on large clinical trial populations and Phase III data, but that approach may not work for a variety of newer targeted drugs, including gene therapies. (more…)
We are excited to announce that Precision Value & Health has been ranked #6 in MM&M magazine’s Agency Top 100 list! With a 10.6% increase in revenue from the previous year, we are continuing to add talent and services–partnering with pharmaceutical and life sciences companies to ensure patient access to life-changing therapies.
In response to the increase in value-focused care, vertical integration among payers and pharmacy benefit managers has increased as well, but what does this mean for manufacturers? (more…)
EXPANDED EMPHASIS ON INTERPRETING THE SCIENCE OF COMPLEX MEDICAL INNOVATIONS
BOLSTERS PRECISION’S CAPABILITIES TO SUPPORT COMMERCIAL AND R&D CLIENT BASE
Bethesda, MD – Tuesday, July 10, 2018 – Precision Medicine Group, LLC., announced it is acquiring ETHOS Health Communications, a Pennsylvania-based agency specializing in the interpretation and communication of innovative medical science. The acquisition of ETHOS, which informs physicians, providers and other stakeholders through medical affairs- and marketing-based scientific content, allows Precision to offer its clients a significantly expanded cadre of doctoral-level science and medical communications specialists.
As more gene and CAR-T therapies enter the market, especially in therapeutic categories with more patients such as cancer, experts say manufacturers will have to up their game in establishing the true value of their therapies, and work closely with payers on payment agreements. Precision for Value experts Jeremy Schafer and Alex Grosvenor offer their perspectives in this MedAd News cover story.
(more…)
To bring gene therapies to market sooner the FDA plans to speed up approvals by evaluating these therapies’ impact on “surrogate end points.” (more…)
Prior authorization (PA) is a time-consuming and costly burden on healthcare providers. With an increase in specialty medication spending, accounting for 70% of total drug spend, PAs are expected to become more stringent and restrictive. Marylou Buyse and Charline Shan share their insight and explore how the vertical integration mergers might impact PA for the better.
A new study by Senior Director, Policy & Economics Julia Thornton Snider, PhD, was recently published in the medical journal Vaccine. (more…)
Challenges persist in measuring value in healthcare, and individual healthcare decision makers need personalized information about value to make informed choices. Precision’s Mark Linthicum, Jennifer Bright, and Jason Shafrin explore an open-source modeling approach to value assessment in an article for Journal of Clinical Pathways.
PHE Senior Research Economist James Baumgardner, PhD, and colleagues conducted an analysis aimed at determining whether spending within oncology care episodes is associated with survival. (more…)